+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the study medicine elranatamab, alone and combined with daratumumab, in people with multiple myeloma who have previously been treated with therapies including lenalidomide. The trial aims to determine whether elranatamab offers more benefit compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone, while also assessing the safety and activity of elranatamab with daratumumab. This is a Phase 3, randomized, open-label study designed to compare these treatment options and to evaluate infection protection measures. The study includes three parts. Part 1 tests the safety and activity of different doses of elranatamab combined with daratumumab. In Part 2, participants are randomly assigned to receive elranatamab alone, elranatamab plus daratumumab, or the combination of daratumumab, pomalidomide, and dexamethasone. Part 3 assesses the impact of enhanced infection protection in participants receiving elranatamab alone or with daratumumab. Treatments are administered subcutaneously or orally as appropriate, and participants continue treatment until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular assessments including monitoring of disease progression, safety evaluations, and adverse event tracking. Key outcome measures include dose-limiting toxicities, progression-free survival, and treatment-emergent adverse events. Other evaluations include overall survival, response rates, duration of response, pharmacokinetics, immunogenicity, and quality of life assessments. Follow-up and monitoring continue for up to 51 months after randomization to capture long-term effects and safety.

Age: 18Years +All GendersPhase 3
237 locations
I

Actively Recruiting

Researchers are evaluating the efficacy and safety of lutetium 177Lu vipivotide tetraxetan AAA617 in adult male participants with oligometastatic prostate cancer OMPC that is progressing after definitive treatment to the primary tumor. The study aims to delay progression to fatal metastatic disease and preserve quality of life by postponing androgen deprivation therapy ADT. This is a Phase III, open-label, randomized trial involving participants with PSMA-positive OMPC. Participants will undergo baseline disease assessments including PETCT scans using gallium 68Ga gozetotide or piflufolastat 18F, along with CTMRI and bone scans. All will receive Stereotactic Body Radiation Therapy SBRT to metastatic lesions over about three weeks. Those in the investigational group will then receive up to four cycles of AAA617 infusions every six weeks. Participants in the control group will be observed after SBRT without additional treatment. Visits occur weekly during cycles and every 16 weeks thereafter until disease progression. During the study, participants will be monitored through regular imaging and clinical assessments to track disease progression and side effects. Outcome measures include metastasis-free survival, time to hormonal therapy, PSA progression, quality of life questionnaires, and safety events, with follow-up lasting approximately 7.5 years. This comprehensive monitoring seeks to understand the treatments impact on delaying progression and maintaining patient well-being over time.

Age: 18Years - 100YearsMALEPhase 3
144 locations
S

Actively Recruiting

Researchers are evaluating the effects of vericiguat compared to placebo in children and adolescents with heart failure caused by left ventricular systolic dysfunction. The study aims to determine if vericiguat can better reduce levels of a heart failure marker called NT-proBNP over 16 weeks. This research is a Phase 23 clinical trial assessing efficacy, safety, and pharmacokinetics in pediatric participants. Participants receive either vericiguat or placebo daily by mouth in tablet or suspension form for 52 weeks during the Base Period. After completing this phase, eligible participants can join an optional open-label Extension Period where they receive vericiguat daily. The study incorporates a previously separate extension arm, allowing long-term follow-up of up to approximately 8 years. Throughout the study, participants will have their NT-proBNP levels measured and monitored at various time points, including baseline, Week 16, Week 52, and during the Extension Period. Researchers will also track adverse events and reasons for stopping the study drug. Additional assessments include heart failure events, pharmacokinetic measurements, and safety evaluations. The total study duration can extend up to 8 years for some participants.

Age: 29Days - 17YearsAll GendersPhase 2Phase 3
111 locations
S

Actively Recruiting

This research aims to evaluate treatments for adult men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC who have previously received androgen receptor pathway inhibitors, taxane-based chemotherapy, and progressed on or after 177LuLu-PSMA targeted therapy. The study includes both Phase II and Phase III portions to gather detailed information on dosing and to compare the investigational treatment AAA817 with standard care. Participants will be randomly assigned to receive either AAA817, given in cycles of 8 weeks, or the investigators choice of standard of care treatment. The Phase II part focuses on supporting the dose of AAA817, while the Phase III part compares the efficacy and safety of AAA817 against standard treatments. The study is open-label and conducted internationally across multiple centers. During the study, participants will be monitored for biochemical responses, adverse events, and disease progression through imaging scans and clinical assessments over approximately 24 months. The research team will track survival rates, disease control, patient-reported symptoms, and quality of life. Safety and tolerability of AAA817 will be evaluated from the start of treatment until several weeks after the last dose. Overall, the study spans several years, including follow-up periods to assess long-term outcomes.

Age: 18Years - 100YearsMALEPhase 2Phase 3
93 locations